Identification of cell-free DNA methylation patterns unique to the human left ventricle as a potential indicator of acute cellular rejection

Clin Transplant. 2021 Jun;35(6):e14295. doi: 10.1111/ctr.14295. Epub 2021 Apr 3.

Abstract

Increased levels of donor-derived cell-free DNA (dd-cfDNA) in recipient plasma have been associated with rejection after transplantation. DNA sequence differences have been used to distinguish between donor and recipient, but epigenetic differences could also potentially identify dd-cfDNA. This pilot study aimed to identify ventricle-specific differentially methylated regions of DNA (DMRs) that could be detected in cfDNA. We identified 24 ventricle-specific DMRs and chose two for further study, one on chromosome 9 and one on chromosome 12. The specificity of both DMRs for the left ventricle was confirmed using genomic DNA from multiple human tissues. Serial matched samples of myocardium (n = 33) and plasma (n = 24) were collected from stable adult heart transplant recipients undergoing routine endomyocardial biopsy for rejection surveillance. Plasma DMR levels increased with biopsy-proven rejection grade for individual patients. Mean cellular apoptosis in biopsy samples increased significantly with rejection severity (2.4%, 4.4% and 10.0% for ACR 0R, 1R, and 2R, respectively) but did not show a consistent relationship with DMR levels. We identified multiple DNA methylation patterns unique to the human ventricle and conclude that epigenetic differences in cfDNA populations represent a promising alternative strategy for the non-invasive detection of rejection.

Keywords: DNA methylation; cell-free DNA; epigenetics; heart; rejection; transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers
  • Cell-Free Nucleic Acids* / genetics
  • DNA Methylation
  • Graft Rejection / etiology
  • Graft Rejection / genetics
  • Heart Ventricles
  • Humans
  • Pilot Projects

Substances

  • Biomarkers
  • Cell-Free Nucleic Acids